Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heliox for Neonatal ARDS
NCT03217149Unknown
- Start
- Sep 2017
- Primary completion
- Aug 2020
- Modality
- GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
Randomised trial of heliox in acute respiratory distress syndrome (ARDS) (2 arms). Primary endpoint: Death at 100 days. Status: unknown.
02
Drugs
heliox
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03217149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217149.